Story perspectives

Harmony Biosciences Halts ZYN002, Eyes New Trials Ahead

11/6/2025

36 3

Summary

Story summary

Harmony Biosciences paused ZYN002 after a Phase III trial for fragile X syndrome failed, citing a high placebo response.
The company is reviewing trial data to decide next steps, including a Phase III study for 22q11.2 deletion syndrome.
22q11.2 deletion syndrome affects about 1 in 4,000 people in the United States.
Harmony Biosciences reported a 29% increase in quarter three (Q3) earnings, driven by Wakix, while continuing trials for pitolisant and EPX-100.

1 of 1

Story summary

Harmony Biosciences paused ZYN002 after a Phase III trial for fragile X syndrome failed, citing a high placebo response.
The company is reviewing trial data to decide next steps, including a Phase III study for 22q11.2 deletion syndrome.
22q11.2 deletion syndrome affects about 1 in 4,000 people in the United States.
Harmony Biosciences reported a 29% increase in quarter three (Q3) earnings, driven by Wakix, while continuing trials for pitolisant and EPX-100.